Sign In
Buy MGRM
$6.00
+0 (+0%)
At Close: Jan 06, 2026
Monogram Technologies Announces Closing of Upsized and Oversubscribed $13 Million Public Offering
06:00pm, Wednesday, 02'nd Oct 2024
AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focu
Monogram Technologies Receives FDA Response for mBôs TKA System
06:00pm, Wednesday, 02'nd Oct 2024
Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"),
Monogram Technologies Announces Preferred Stock Dividends
08:31am, Tuesday, 01'st Oct 2024
AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focu
Monogram Technologies Upsizes 8.00% Series D Convertible Cumulative Preferred Stock and Warrant Offering to $12.5 Million
05:55pm, Wednesday, 11'th Sep 2024
AUSTIN, TX / ACCESSWIRE / September 11, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial f
Monogram Technologies Reports Second Quarter 2024 Financial Results
04:05pm, Wednesday, 14'th Aug 2024
Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA System Secured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby Limited Management to Host
Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration
08:30am, Monday, 12'th Aug 2024
Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA System Strategic Partner Shalby is Recognized a
Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance
08:00am, Thursday, 08'th Aug 2024
Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review FDA Decision is Expected Within 90 Days of Initial Submission; However, the Proces
AUSTIN, TX / ACCESSWIRE / August 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus
Monogram Technologies to Host Investor and Analyst Tour at its Headquarters in Austin, Texas, on Thursday, June 20th, 2024
08:31am, Monday, 03'rd Jun 2024
Management to Showcase Product Demonstration of mBôs Precision Robotic Surgical System and mVision Technologies AUSTIN, TX / ACCESSWIRE / June 3, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Mon
Monogram Technologies Inc. (MGRM) Q1 2024 Earnings Call Transcript
07:54pm, Wednesday, 22'nd May 2024
Monogram Technologies Inc. (NASDAQ:MGRM ) Q1 2024 Earnings Conference Call May 22, 2024 4:30 PM ET Company Participants Larry Holub - Investor Relations, MZ Group North America Noel Knape - Chief Fina
Monogram Orthopaedics Completes Corporate Name Change to Monogram Technologies
08:31am, Wednesday, 15'th May 2024
New Name Reflects Continued Evolution as an AI-Driven Robotics Company with a Strong IP Position AUSTIN, TX / ACCESSWIRE / May 15, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "C
Monogram Orthopaedics Reports First Quarter 2024 Financial Results
09:17am, Tuesday, 14'th May 2024
Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half of 2024 Engaged Contract Research Organization to Oversee mBôs R
Monogram Engages Contract Research Organization to Oversee mBôs Robot Clinical Trial Activities Outside the U.S.
08:31am, Monday, 13'th May 2024
CRO Expands Clinical Capabilities, Accelerating Product Pipeline Development and Commercialization Opportunities AUSTIN, TX / ACCESSWIRE / May 13, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Mon
Monogram Provides Regulatory Update Following Meeting with FDA
08:00am, Wednesday, 01'st May 2024
510(k) Submission with FDA Accelerated for Early Second Half of 2024 AUSTIN, TX / ACCESSWIRE / May 1, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven roboti
Monogram Accepted to NVIDIA Inception Program
01:20pm, Thursday, 11'th Apr 2024
Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs System AUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM
